Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges.
about
Cys34-PEGylated Human Serum Albumin for Drug Binding and DeliveryIn vitro determination of drug transfer from drug-coated balloonsLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Flow-focusing regimes for accelerated production of monodisperse drug-loadable microbubbles toward clinical-scale applicationsInfluence of Study Design Variables on Clinical Pathology Data.Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.Subcutaneous administration of paclitaxel in dogs with cancer: A preliminary study.Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes.Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?Self-assembled Tat nanofibers as effective drug carrier and transporter.Status and Prospects of Aptamers as Drug Components.Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapeutics development.Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization.Technetium-99m radiolabeled paclitaxel as an imaging probe for breast cancer in vivoLactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma.Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts.Noncovalent interaction-assisted drug delivery system with highly efficient uptake and release of paclitaxel for anticancer therapy.Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro.Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies.Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery.Aminoglucose-functionalized, redox-responsive polymer nanomicelles for overcoming chemoresistance in lung cancer cells.Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery.Biotinylated Cyclooligosaccharides for Paclitaxel Solubilization.Characteristics, Properties and Analytical Methods of Paclitaxel: A Review.Characterisation, in-vitro and in-vivo evaluation of valproic acid-loaded nanoemulsion for improved brain bioavailability.Pullulan-coated phospholipid and Pluronic F68 complex nanoparticles for carrying IR780 and paclitaxel to treat hepatocellular carcinoma by combining photothermal therapy/photodynamic therapy and chemotherapy.Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry.
P2860
Q27301475-ACA1DDE1-D9C1-4FDA-9C2E-46D57880E60FQ28538166-0F3FC635-3235-4996-8FC3-51F3D9577D39Q30366990-9B9641FC-2B62-4FEE-8A07-8DD312A92E7BQ30422675-2609C9D3-D380-465E-B039-19F7F762F178Q31160507-1F6C2BCD-D8B1-4D14-B7FD-71049DE7451CQ33848124-B83CC686-2DBD-49F3-86AF-6BC258982C8AQ35853317-3A79D9B4-B13F-4EF0-85EF-DB0E584F8CCFQ36076485-2CC7AE65-5C0E-4558-927E-21A0EC0F5685Q36682970-0F85E261-DC35-4661-AB71-48E9B60F30AFQ36860835-1E5262D4-B461-4FDB-A1BE-8BF2D2A79FECQ37237907-538B1474-FEC3-4149-A4FD-E02ECE2CA239Q38488502-AACDA1F5-A260-4292-ADE6-CAF20B95FD0DQ38708186-6897EAE5-1B0C-49AC-ACAA-EFA143433FABQ38844243-8653D62C-87D8-4A1E-98D5-C82260AED185Q38949920-7921392A-005D-465B-9D20-383E21F4CE03Q39030165-FFC6DAF0-B3D1-4EEB-8377-B1955D9E1254Q41421955-718FD6D2-F7BB-49C3-B81E-4230574CCB8AQ42283138-58FC937F-8FBC-4490-B4E5-931A0B82DDEBQ42285180-3F7F8573-93B0-4D7B-8A9A-B7906B033EF6Q42658800-6BDD4972-908B-4E03-A735-A5FAD245C786Q45932069-120BDC12-C75F-4D9F-80FD-F509D0B87EF5Q46079741-4B693CAE-60DE-4870-8697-4C078FA0C8CBQ47123718-E6B49C84-B7FA-4FE5-B763-DD3FEC6F6932Q47682165-9340F674-9FA4-479E-BDD1-3B77E4398A32Q47731737-D1596BFC-40D3-4C23-9906-D26754BE1663Q47756052-C5471137-CBD2-4571-94D5-43FCE9D8D524Q48153806-A212C059-D768-47A4-A275-3149F02B2B3DQ48564875-46A1A035-4CB6-417C-B17C-D042EAE44E54Q50897687-3A482145-9E8C-4D1F-ABC7-8396E69911F0
P2860
Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Designing Paclitaxel drug deli ...... current status and challenges.
@ast
Designing Paclitaxel drug deli ...... current status and challenges.
@en
type
label
Designing Paclitaxel drug deli ...... current status and challenges.
@ast
Designing Paclitaxel drug deli ...... current status and challenges.
@en
prefLabel
Designing Paclitaxel drug deli ...... current status and challenges.
@ast
Designing Paclitaxel drug deli ...... current status and challenges.
@en
P2093
P2860
P356
P1433
P1476
Designing Paclitaxel drug deli ...... current status and challenges.
@en
P2093
Madhu S Surapaneni
Nandita G Das
Sudip K Das
P2860
P304
P356
10.5402/2012/623139
P577
2012-08-12T00:00:00Z